Mount Sinai-Anthem Contract Collapses as Cigna Names Evanko CEO in a Week That Reshaped Carrier Power

The week of March 2 to March 8, 2026 was one of those rare seven-day stretches in which the structural assumptions of the U.S. health insurance market all moved at once. At midnight on Tuesday, March 3, Mount Sinai Health System's hospitals joined nine thousand of its physicians outside Anthem Blue Cross Blue Shield's commercial network, ending a thirteen-week regulatory grace period and sending two hundred thousand New Yorkers into out-of-network territory. Hours later, before the East Coast trading session opened, The Cigna Group disclosed that David Cordani — the CEO who reshaped the company across seventeen years from a regional insurer into a $275 billion global health platform — would step down July 1 in favor of President and Chief Operating Officer Brian Evanko. UnitedHealth Group's annual report had landed the day prior with a footnote that drew its own headlines: a subsidiary list that had run to roughly 3,100 entities the year before now showed only ten. And underneath all of it, the first individual marketplace enrollees were beginning to pay the full price of the enhanced premium tax credit expiration that Congress allowed to lapse on January 1. By the close of the week the question facing brokers, plan sponsors, and individual enrollees was less about any single story than about whether the carrier consolidation, leadership turnover, and subsidy retrenchment that defined early 2026 had now compounded into something durable.

Mount Sinai Goes Dark on Anthem at Midnight

The Mount Sinai-Anthem dispute had been telegraphed since New Year's Eve, when the parties' contract formally lapsed and roughly nine thousand Mount Sinai physicians moved to out-of-network status for Anthem's commercial members. New York's continuity-of-care statute spared the hospital system itself for sixty days, and a temporary extension on February 23 pushed the hospital deadline to midnight on Tuesday, March 3. When the clock ran out without a deal, Mount Sinai's hospitals — including The Mount Sinai Hospital, Mount Sinai West, Mount Sinai Morningside, Mount Sinai Brooklyn, Mount Sinai Queens, Mount Sinai South Nassau, and the Mount Sinai Beth Israel campuses — became out-of-network providers for the roughly two hundred thousand Anthem members who had been treating there. Anthem said in a statement that "patients deserve high-quality care at predictable prices" and that Mount Sinai had sought rate increases "more than 50 percent higher" than market norms. Mount Sinai countered through its Keep Mount Sinai campaign that its proposal called for "single-digit annual increases over three years" and that Anthem's claim was a misrepresentation. The system also restated its position that Anthem owes more than $450 million for previously delivered care, an accounting dispute that has now bled into the rate negotiation in ways that make a clean resolution harder.

The patient impact was immediate and concrete. Anthem committed to honoring continuity-of-care extensions through March 31 for members already engaged in active or serious treatment — pregnancies past the second trimester, ongoing oncology regimens, post-surgical follow-up — and CBS New York reported that the carrier's call centers were directing other members to network alternatives in the New York-Presbyterian, NYU Langone, and Northwell systems. Self-funded employers headquartered in Manhattan, where Mount Sinai often serves as a tertiary referral anchor, spent the week fielding access questions from employees whose primary care relationships were now on the wrong side of an out-of-network bill. The dispute also restarted a debate New York health-policy analysts have been having for years about whether the state's continuity-of-care statute, designed in an era of more cooperative provider-payer relationships, now functions less as a patient protection and more as a structured countdown to leverage exhaustion. By the end of the week the contract was still not signed, and the negotiating posture on both sides had hardened publicly enough that a quick settlement looked unlikely.

Cordani's Exit and the Rebate Pivot at Cigna

Before the markets opened on the same March 3, The Cigna Group announced that David Cordani would retire as Chief Executive Officer effective July 1 and become Executive Chair of the Board, with Brian Evanko — Cigna's forty-nine-year-old president and chief operating officer — succeeding him. Evanko has spent more than three decades inside the company and currently oversees both the insurance segment, Cigna Healthcare, and the health services unit, Evernorth, which houses the Express Scripts pharmacy benefit manager. Cordani's tenure was, by any measure, the most consequential in Cigna's modern history. He took the helm of a traditional insurer serving roughly forty-six million customers and generating eighteen billion dollars of annual revenue and leaves a global health company with one hundred eighty million customer relationships and approximately two hundred seventy-five billion dollars in annual revenue. Along the way he engineered the Express Scripts acquisition, exited the Medicare Advantage business through a sale to Health Care Service Corporation, and attempted — unsuccessfully — a UnitedHealth-style integration through a 2023 merger play with Humana that fell apart over price.

The transition arrives mid-pivot. Cigna disclosed in late 2025 that it was shifting commercial customers to a pharmacy model that excludes manufacturer rebates from the supply chain, a move the company has acknowledged will compress margins for the next two years before it expects the volume effects to compensate. Evanko inherits that strategy, the operational cleanup of the Cordani-era acquisitions, and a regulatory environment in which the Consolidated Appropriations Act of 2026 has rewritten the rules for PBMs by requiring one hundred percent rebate pass-through to ERISA plans starting with plan years on or after July 1, 2026. Cigna reaffirmed its 2026 financial guidance as part of the announcement — a deliberate signal to investors that the leadership change would not produce a strategic reset, and that the rebate restructuring already in motion was the operating plan Evanko intended to execute. Cordani's last quarter on the job will be CEO of a company simultaneously absorbing a federal PBM reform package, an FTC consent order against Express Scripts that takes effect January 1, 2027, and a market-wide repricing of pharmacy economics that few in Washington predicted would all land in the same year.

UnitedHealth's Subsidiary Disclosure Shrinks to Ten

The same news cycle delivered a quieter but unusually pointed disclosure from UnitedHealth Group. The company's Form 10-K, filed with the SEC on Monday, March 2, listed only ten subsidiaries in its annual report's required exhibit — a dramatic compression from the roughly three thousand one hundred entities the company had disclosed in its prior 10-K. The reduction is technically permissible under SEC Regulation S-K Item 601(b)(21), which requires registrants to identify only "significant" subsidiaries, but the optics arrive at a moment when UnitedHealth is already navigating Department of Justice criminal and civil investigations into its Medicare Advantage billing practices and Optum Rx's reimbursement behavior. The combination of an ongoing federal probe and a sharp shrinkage in the publicly named corporate footprint produced commentary across the trade press that a company under this kind of scrutiny might be expected to lean toward more disclosure rather than less. UnitedHealth, for its part, did not announce the change with any accompanying explanation; the disclosure shift surfaced through analyst inspection of the filing itself.

For employer plan sponsors using UnitedHealthcare's administrative services platform or for brokers placing Optum Rx pharmacy contracts, the practical effect of the disclosure compression is minimal in the near term. Contract counterparties remain identifiable through state insurance department filings and the company's own subsidiary documentation. The longer-term concern, voiced by several plan-sponsor advisors during the week, is that the trend toward consolidated parent-level disclosure can complicate ERISA fiduciary review of conflicts of interest and related-party arrangements at exactly the moment that PBM transparency rules are demanding more granular accounting from intermediaries.

The Subsidy Cliff Shows Up on Statements

Beneath the carrier headlines, the largest demand-side story of the year continued to spread through individual marketplace households. The enhanced premium tax credits that had capped marketplace premium contributions since 2021 expired January 1, 2026, and by early March the first wave of enrollees were receiving statements that reflected the change at full force. Congressional Budget Office and Kaiser Family Foundation modeling projected the average subsidized enrollee's annual premium contribution would more than double — from approximately $888 in 2025 to roughly $1,904 in 2026 — and individual filings reviewed during the week confirmed the magnitude on the ground. A single individual at one hundred forty percent of the federal poverty level, who in 2025 enrolled in a zero-premium silver plan with cost-sharing reductions, was now seeing a monthly premium of approximately $66, an annual increase of $786. Households above four hundred percent of the federal poverty level — the so-called "subsidy cliff" population reinstated by the expiration — were seeing the steepest absolute increases, in many cases several thousand dollars per year.

The cumulative effect on enrollment is still being measured. CMS data released later in the month would show that average out-of-pocket premiums for marketplace enrollees rose from $113 to $178 per month between 2025 and 2026, a $65 monthly increase that aligns with the CBO projection band. Brokers serving the individual market reported a notable bifurcation through the first quarter: lower-income enrollees were largely staying on coverage as the cost-sharing reduction structure absorbed the worst of the premium shock, while higher-income marketplace members above the cliff threshold were shopping aggressively, dropping coverage, or moving to short-term limited-duration products that the Trump administration has expanded under regulations finalized late in 2025.

Three CMS Threads Converging in March

Three federal regulatory threads continued to advance through the same week, none with new headlines but all meaningfully affecting the calendar plan sponsors and brokers were watching:

• The CMS Notice of Benefit and Payment Parameters for plan year 2027, proposed in February, remained in its public comment period — comments due March 13 — with marketplace standard plans, catastrophic eligibility expansion, and stricter integrity provisions all in scope.
• The CRUSH Request for Information published February 27 was accumulating comments toward a March 30 deadline, with provider, supplier, and payer trade associations preparing responses on AI-assisted pre-payment audits.
• The CY 2027 Medicare Advantage Advance Notice, with comments closed February 25, remained on track for an April 6 final notice that the Office of the Actuary's preliminary +0.09 percent net rate update would not survive without further industry pressure.

Industry attorneys at Foley Hoag and Hall Render flagged the unusual stacking of comment deadlines in March as a stress test for trade-association policy shops, several of which have been running short-staffed since the federal hiring freezes and contract pauses that accompanied the early Trump administration restructuring. The volume of comment work landing in the same window is itself a regulatory phenomenon: plan-year 2027 marketplace rules, anti-fraud rulemaking, and Medicare Advantage rate-setting are all converging into one decision window for an industry already absorbing leadership transitions, contract failures, and a subsidy retrenchment whose full effects will not be visible until the next open enrollment cycle.

The Story Beneath the Stories

What the week of March 2 demonstrated, taken together, was that the carrier-power story driving most of 2026's headlines had moved from anticipation into execution. Mount Sinai-Anthem proved that even in a state with strong continuity-of-care protections, the leverage equation between an integrated health system and a national payer can run all the way out and produce an actual out-of-network event affecting hundreds of thousands of members. Cigna's leadership change confirmed that the post-Cordani era of integrated-payer strategy is being handed to an operator rather than a deal-maker, in a regulatory environment where PBM economics are being legislated rather than negotiated. UnitedHealth's disclosure compression underscored that the largest carrier in the market is reorganizing the visibility of its corporate structure even as the Department of Justice continues to pursue its billing practices. And the subsidy cliff, which had been a theoretical conversation through most of 2025, was now showing up as actual dollars on actual statements for individual enrollees who, in many cases, had not realized the change was coming. None of these stories started this week. All of them advanced, materially, in the same seven days. The week ahead would carry Mount Sinai-Anthem into its second week of out-of-network status, push the 2027 NBPP into the closing days of its comment period, and bring the next round of state Medicaid CRUSH letters into focus — a March that, after only seven days, was already producing more change in carrier and regulatory architecture than any single quarter of the prior year.